Article
Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer.
International journal of oncology - 1 Aug 2017
Yamashita Takahisa, Higashi Morihiro, Momose Shuji, Morozumi Makoto, Tamaru Jun-Ichi
Abstract excerpt
The development and acquisition of multiple drug resistance in cancer cells remain a major obstacle in the treatment of bladder cancer. Nuclear translocation of Y box binding-1 (YB-1), which is a member of a family of DNA-binding proteins that contain a cold shock domain, plays a significant role in the acquisition of drug resistance by upregulating expression of the multidrug resistance-1 (MDR-1) gene product,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
